Research Article
A flexible unified approach to the analysis of pre‐clinical combination studies
Abstract
Combinations of drugs are increasingly being used in a variety of diseases. Pre‐clinical experiments allow the responses of many drug compounds to be studied in combination with the goal of identifying compounds acting synergistically. This paper presents a unified approach to analysing data from combination studies, calculating a hierarchy of interaction indices to powerfully and flexibly describe the synergistic profile of the combination space studied, utilizing standard statistical software to generate estimates of confidence and provide statistical tests. The approach can work with a wide variety of experimental designs and response patterns and will deal with partial responses and inactive compounds. As well as identifying synergy or antagonism, the same approach can also be used to identify a benefit or detriment to monotherapy. The approach is illustrated with data from an in vitro study. Copyright © 2010 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited according to CrossRef: 15
- Yvonne Azasi, Shannon K. Gallagher, Ababacar Diouf, Rebecca A. Dabbs, Jing Jin, Syed Yusuf Mian, David L. Narum, Carole A. Long, Deepak Gaur, Simon J. Draper, Michael P. Fay, Louis H. Miller, Kazutoyo Miura, Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations, Scientific Reports, 10.1038/s41598-020-67877-8, 10, 1, (2020).
- Simon Lea, Jian Li, Jonathan Plumb, Kate Gaffey, Sarah Mason, Rosie Gaskell, Chris Harbron, Dave Singh, P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells, Journal of Molecular Medicine, 10.1007/s00109-020-01873-3, (2020).
- Linda M. Haines, Gaëtan M. Kabera, Principal Ndlovu, -optimal designs for the two-variable binary logistic regression model with interaction , Journal of Statistical Planning and Inference, 10.1016/j.jspi.2017.08.007, 193, (136-150), (2018).
- Fabiola La Gamba, Tom Jacobs, Helena Geys, Luc Ver Donck, Christel Faes, A Bayesian K‐PD model for synergy: A case study, Pharmaceutical Statistics, 10.1002/pst.1887, 17, 6, (674-684), (2018).
- Qin Liu, Xiangfan Yin, Lucia R. Languino, Dario C. Altieri, Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1437071, 10, 2, (112-122), (2018).
- Esther M. Speer, David J. Dowling, Jianjin Xu, Lukasz S. Ozog, Jaime A. Mathew, Avinash Chander, Donglei Yin, Ofer Levy, Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro, PLOS ONE, 10.1371/journal.pone.0196352, 13, 5, (e0196352), (2018).
- Koen Van der Borght, Annelies Tourny, Rytis Bagdziunas, Olivier Thas, Maxim Nazarov, Heather Turner, Bie Verbist, Hugo Ceulemans, BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism, Scientific Reports, 10.1038/s41598-017-18068-5, 7, 1, (2017).
- Yubing Wan, Susmita Datta, J. Jack Lee, Maiying Kong, Monotonic single‐index models to assess drug interactions, Statistics in Medicine, 10.1002/sim.7158, 36, 4, (655-670), (2016).
- Lanju Zhang, Hyuna Yang, Design and Evaluation of Drug Combination Studies, Nonclinical Statistics for Pharmaceutical and Biotechnology Industries, 10.1007/978-3-319-23558-5_13, (349-363), (2016).
- Matthew Sperrin, Helene Thygesen, Ting‐Li Su, Chris Harbron, Anne Whitehead, Experimental designs for detecting synergy and antagonism between two drugs in a pre‐clinical study, Pharmaceutical Statistics, 10.1002/pst.1676, 14, 3, (216-225), (2015).
- Judith Michels, Ilio Vitale, Laura Senovilla, David P. Enot, Pauline Garcia, Delphine Lissa, Ken A. Olaussen, Catherine Brenner, Jean-Charles Soria, Maria Castedo, Guido Kroemer, Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer, Cell Cycle, 10.4161/cc.24034, 12, 6, (877-883), (2014).
- Elodie Lainey, Marie Sébert, Sylvain Thépot, Marie Scoazec, Cyrielle Bouteloup, Carole Leroy, Stéphane De Botton, Lorenzo Galluzzi, Pierre Fenaux, Guido Kroemer, Erlotinib antagonizes ABC transporters in acute myeloid leukemia, Cell Cycle, 10.4161/cc.22382, 11, 21, (4079-4092), (2014).
- Anne Whitehead, Ting‐Li Su, Helene Thygesen, Matthew Sperrin, Chris Harbron, Investigation of the robustness of two models for assessing synergy in pre‐clinical drug combination studies, Pharmaceutical Statistics, 10.1002/pst.1583, 12, 5, (300-308), (2013).
- Wei Zhao, Lanju Zhang, Lingmin Zeng, Harry Yang, A Two-Stage Response Surface Approach to Modeling Drug Interaction, Statistics in Biopharmaceutical Research, 10.1080/19466315.2012.707087, 4, 4, (375-383), (2012).
- J. Armstrong, C. Harbron, S. Lea, G. Booth, P. Cadden, K. A. Wreggett, D. Singh, Synergistic Effects of p38 Mitogen-Activated Protein Kinase Inhibition with a Corticosteroid in Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.111.180737, 338, 3, (732-740), (2011).
